Insufficient sample tissue and conflicting legal and regulatory requirements increasingly pose a practical obstacle for the implementation of precision medicine testing for patient treatment protocols and clinical trial research. While shift away from a single biomarker testing to next generation sequencing and advances in science and practice of pathology provide some solutions to the problem, significant changes to laws, regulations, IRB reviews, and patient informed consent may be required to address the issue.